2. Search Result
Search Result
Results for "

GSK-A1

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

2

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125118
    GSK-A1

    		PI4K HCV Infection
    GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research [1].
    <em>GSK-A1</em>
  • HY-128888A
    (S,S)-GSK321

    		Isocitrate Dehydrogenase (IDH) Cancer
    (S,S)-GSK321 is a (S,S)-enantiomer of GSK321 .
    (S,S)-<em>GSK</em>321
  • HY-120343
    GSK106

    		Protein Arginine Deiminase Cardiovascular Disease Inflammation/Immunology Cancer
    GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199 .
    <em>GSK</em>106
  • HY-100546A
    GSK-LSD1 dihydrochloride
    5 Publications Verification

    		 Histone Demethylase Monoamine Oxidase Cancer
    GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC50 of 16 nM.
    <em>GSK-LSD1</em> dihydrochloride
  • HY-100546
    GSK-LSD1

    GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis [1] .
    <em>GSK-LSD1</em>
  • HY-15648A
    GSK-J2
    2 Publications Verification

    		 Others Cancer
    GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A.
    <em>GSK</em>-J2
  • HY-100603
    GSK-F1

    GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research [1].
    <em>GSK-F1</em>
  • HY-15648I
    GSK-J2 sodium

    		Others Cancer
    GSK-J2 sodium is the sodium form of GSK-J2 (HY-15648A). GSK-J2 is an isomer of GSK-J1, and does not have any specific activity. GSK-J1 (HY-15648) is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A [1].
    <em>GSK</em>-J2 sodium
  • HY-19654B
    (-)-GSK598809

    (1S,5R)-GSK598809

    		 Dopamine Receptor Others
    (-)-GSK598809 ((1S,5R)-GSK598809) is an isomer of GSK598809. GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist.
    (-)-<em>GSK</em>598809
  • HY-P1114
    2B-(SP)

    		GSK-3 Neurological Disease
    2B-(SP) is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) is readily phosphorylated by both the α and β isoforms of GSK-3 .
    2B-(SP)
  • HY-P1114A
    2B-(SP) (TFA)

    		GSK-3 Cancer
    2B-(SP) TFA is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) TFA is readily phosphorylated by both the α and β isoforms of GSK-3 .
    2B-(SP) (TFA)
  • HY-15648
    GSK-J1
    5+ Cited Publications

    		 Histone Demethylase Cancer
    GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 of 60 nM towards KDM6B.
    <em>GSK-J1</em>
  • HY-15648D
    GSK-J1 lithium salt

    		Histone Demethylase Cancer
    GSK-J1 lithium salt is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 of 60 nM towards KDM6B.
    <em>GSK-J1</em> lithium salt
  • HY-15648G
    GSK-J1 sodium

    		Histone Demethylase Cancer
    GSK-J1 sodium is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 value of 60 nM towards KDM6B [1] .
    <em>GSK-J1</em> sodium
  • HY-155723
    Leucettinib-92

    		CDK DYRK Others
    Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC50s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .
    Leucettinib-92
  • HY-15648F
    GSK-J4 hydrochloride
    Maximum Cited Publications
    34 Publications Verification

    		 Histone Demethylase Cancer
    GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 [1] .
    <em>GSK</em>-J4 hydrochloride
  • HY-15648B
    GSK-J4
    Maximum Cited Publications
    34 Publications Verification

    		 Histone Demethylase Apoptosis Cancer
    GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 [1] . GSK-J4 induces endoplasmic reticulum stress-related apoptosis .
    <em>GSK</em>-J4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: